CytomX Therapeutics to Present at Upcoming June Investor Conferences
Rhea-AI Summary
CytomX Therapeutics (Nasdaq: CTMX) announced management participation in two June 2026 investor conferences. Events include fireside chats and one-on-one investor meetings.
Jefferies Global Healthcare Conference: June 4, 2026, 3:10 p.m. ET, New York, NY. Goldman Sachs 47th Annual Global Healthcare Conference: June 10, 2026, 9:20 a.m. ET, Miami, FL. Live webcasts will be available on CytomX’s website.
Positive
- None.
Negative
- None.
News Market Reaction – CTMX
In the May 21 session, CTMX gained 1.08%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Regulatory hire | Positive | -3.0% | Appointment of senior regulatory affairs leader for PROBODY pipeline. |
| May 7 | Earnings & update | Neutral | -0.5% | Q1 2026 results with lower revenue and extended cash runway. |
| Apr 30 | Earnings date set | Neutral | +4.2% | Announcement of date and time for Q1 2026 results call. |
| Mar 17 | Offering priced | Negative | -19.3% | Pricing of common stock and pre-funded warrant offering. |
| Mar 16 | Offering proposed | Negative | -19.3% | Announcement of proposed public equity and warrant offering. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News-driven moves mostly align with the nature of announcements, with offerings drawing sharp declines and earnings or scheduling items seeing milder reactions; one executive hire headline coincided with a contrary pullback.
Over the last six months, CytomX has combined capital raising and pipeline advancement with governance and leadership updates. In March 2026, proposed and priced equity offerings led to ~19% single-day declines on consecutive sessions. Q1 2026 results on May 7 highlighted sharply lower revenue but a strengthened cash position. An earnings-date notice on April 30 saw a 4.2% gain, while a senior regulatory hire on May 18 coincided with a modest decline. Today’s conference-participation news fits into this pattern of ongoing investor outreach.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the following investor conferences in June.
Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY
Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL
A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (“ADCs”), cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated ADC armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Amgen, Regeneron and Moderna. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit www.cytomx.com and follow us on LinkedIn and X (formerly Twitter).
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
cogden@cytomx.com
Investor Contact:
Precision AQ
Stephanie Ascher
stephanie.ascher@precisionaq.com
Media Contact:
Precision AQ
Colleen Ketchum
colleen.ketchum@precisionaq.com
